Flamingo-01 Phase III GP2 Product Press Releases Email Alerts

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED PHASE IIB CLINICAL TRIAL
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED PHASE IIB CLINICAL TRIAL
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

Presentations

Nasdaq: GLSI

Investors

Overview
News & Events
Company Info
- FAQ
Stock Info
SEC Filings
Governance

Company Info
FAQ

Please check back soon for updates.

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable scripts in your browser and reload the page.